Syndax Pharmaceuticals Soars 11.56% on Soleus Capital Investment

Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) shares surged 11.56% in pre-market trading on May 23, 2025, driven by a significant investment from Soleus Capital Management L.P. The firm acquired 1,401,016 shares, marking a substantial increase in its stake in the company.

This investment comes at a time when Syndax is making strides in its clinical development programs. The company recently announced positive interim data from its Phase 2 trial of sotorasib, a KRAS inhibitor, in patients with non-small cell lung cancer (NSCLC). The data showed promising efficacy and a favorable safety profile, which has bolstered investor confidence in the drug's potential.

Additionally, Syndax has been expanding its pipeline through strategic partnerships and acquisitions. The company recently entered into a collaboration with a leading biotech firm to develop novel therapies for rare diseases, further enhancing its growth prospects. These developments have positioned Syndax as a key player in the oncology and rare disease markets, attracting the attention of institutional investors.

The surge in Syndax's stock price reflects the market's optimism about the company's future prospects. With a strong pipeline and strategic investments, Syndax is well-positioned to capitalize on the growing demand for innovative cancer treatments and rare disease therapies. Investors are closely watching the company's progress, anticipating further positive developments that could drive its stock price even higher.